Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy inJapan- Calliditas Therapeutics AB *Japan Intractable Disease Information Center CONTACT: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:...
Comunicato Precedente
Comunicato Successivo
STOCKHOLM,
(informazione.it - comunicati stampa - scienza e tecnologia)
*Japan Intractable Disease Information Center
CONTACT:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email:
[email protected]
The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189479.html
Ufficio Stampa
